Safety Study of AZD5672 in Renally Impaired Subjects

Inclusion Criteria: * Provision of signed written informed consent. * Females should not be of childbearing potential * Subjects classified as renally impaired should have been stable (in the Investigator's opinion) for at least 3 months prior to Visit 1. Exclusion Criteria: * Patients taking prescription of medications: Pgp substrates, inhibitors and /or inducers, medications that affect creatinine clearance(within 7 days of dosing), atorvastatin \>20mg once daily, medications that prolong QT/QTc interval * Change in dose regimen of prescribed medication and NSAIDs within the 2 weeks before enrolment (renal patients only) * Participation in another clinical study involving administration of an investigational product in the 3 months prior to treatment (or within 5 half-lives of the last dose of the investigational product, whichever is longer)